Clinical Trial

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Name: Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC — clinical trial record (NCT05950139)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ARCHER

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.

Protocol Amendment History 1 change

notable Primary completion pushed: 2026-07 -> 2027-07 2026-07-29

Trial Details

NCT Number	NCT05950139
Lead Sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Collaborators: Oncovir, Inc.
Conditions	NSCLC Stage IV, ALK Fusion Protein Expression
Enrollment	12 participants
Start Date	2024-05-13
Primary Completion	2027-07 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-28